Literature DB >> 7992850

Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease.

C R Harrington1, J Louwagie, R Rossau, E Vanmechelen, R H Perry, E K Perry, J H Xuereb, M Roth, C M Wischik.   

Abstract

Alzheimer's disease (AD) is associated with an increased frequency of the apolipoprotein E type epsilon 4 allele. To address both the disease and the allele specificity of this association, we have examined the apolipoprotein E allele distribution in 255 elderly persons including those with autopsy-confirmed AD, senile dementia of the Lewy body type (SDLT), vascular dementia, Parkinson's disease (PD) or Huntington's disease and in nondemented controls either with or without coronary complications. The epsilon 4 allele frequency was increased in SDLT (0.365) and AD (0.328) as compared with controls (0.147), PD (0.098), or Huntington's chorea (0.171). Coronary disease and vascular dementia were associated with marginally higher epsilon 4 allele frequencies than in controls. In PD, amyloid beta-protein accumulated to a greater extent in those cases possessing an epsilon 4 allele than in those without. Those PD cases with dementia were not distinguished from either controls or PD cases without dementia, whether tested biochemically or by apolipoprotein E genotype. It is the comparison of the results in AD and SDLT that yielded the most significant findings. There was a 1.8-fold excess of amyloid beta-protein in AD as compared with controls, and the levels in SDLT were intermediate between those in AD and controls. In contrast, AD was discriminated from both controls and SDLT by the substantial accumulation of paired helical filament tau and phosphorylated tau (both increased more than 20-fold as compared with controls). SDLT was nevertheless characterized by an increased epsilon 4 allele frequency in the absence of significant tau pathology (at least 10-fold less than that in AD). These findings indicate that tau processing is more specifically associated with AD than is amyloid beta-protein accumulation and that presence of the epsilon 4 allele is not an etiological factor that accounts for tau pathology.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7992850      PMCID: PMC1887513     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  74 in total

1.  Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes.

Authors:  J F Diedrich; H Minnigan; R I Carp; J N Whitaker; R Race; W Frey; A T Haase
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

2.  Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease.

Authors:  C R Harrington; E B Mukaetova-Ladinska; R Hills; P C Edwards; E Montejo de Garcini; M Novak; C M Wischik
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

3.  ApoE genotype and Down's syndrome.

Authors:  J Hardy; R Crook; R Perry; R Raghavan; G Roberts
Journal:  Lancet       Date:  1994-04-16       Impact factor: 79.321

Review 4.  Apolipoprotein E: structure-function relationships.

Authors:  K H Weisgraber
Journal:  Adv Protein Chem       Date:  1994

5.  ApoE and ACE genes: impact on human longevity.

Authors:  F M van Bockxmeer
Journal:  Nat Genet       Date:  1994-01       Impact factor: 38.330

6.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease.

Authors:  Y Namba; M Tomonaga; H Kawasaki; E Otomo; K Ikeda
Journal:  Brain Res       Date:  1991-02-08       Impact factor: 3.252

7.  Regional differences in apolipoprotein E immunoreactivity in diffuse plaques in Alzheimer's disease brain.

Authors:  E Kida; A A Golabek; T Wisniewski; K E Wisniewski
Journal:  Neurosci Lett       Date:  1994-02-14       Impact factor: 3.046

8.  Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro.

Authors:  B P Nathan; S Bellosta; D A Sanan; K H Weisgraber; R W Mahley; R E Pitas
Journal:  Science       Date:  1994-05-06       Impact factor: 47.728

9.  The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations.

Authors:  D M Hallman; E Boerwinkle; N Saha; C Sandholzer; H J Menzel; A Csázár; G Utermann
Journal:  Am J Hum Genet       Date:  1991-08       Impact factor: 11.025

Review 10.  Role of the beta-amyloid precursor protein in Alzheimer's disease.

Authors:  F Ashall; A M Goate
Journal:  Trends Biochem Sci       Date:  1994-01       Impact factor: 13.807

View more
  22 in total

1.  Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease.

Authors:  E B Mukaetova-Ladinska; F Garcia-Siera; J Hurt; H J Gertz; J H Xuereb; R Hills; C Brayne; F A Huppert; E S Paykel; M McGee; R Jakes; W G Honer; C R Harrington; C M Wischik
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease.

Authors:  D W Tsuang; R K Wilson; O L Lopez; E K Luedecking-Zimmer; J B Leverenz; S T DeKosky; M I Kamboh; R L Hamilton
Journal:  Neurology       Date:  2005-02-08       Impact factor: 9.910

3.  Gender and Pathology-Specific Effect of Apolipoprotein E Genotype on Psychosis in Alzheimer's Disease.

Authors:  Julia Kim; Corinne E Fischer; Tom A Schweizer; David G Munoz
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

Review 4.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.

Authors:  Chia-Chen Liu; Chia-Chan Liu; Takahisa Kanekiyo; Huaxi Xu; Guojun Bu
Journal:  Nat Rev Neurol       Date:  2013-01-08       Impact factor: 42.937

5.  APOE ε4 influences β-amyloid deposition in primary progressive aphasia and speech apraxia.

Authors:  Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Val J Lowe; Clifford R Jack; Jennifer L Whitwell
Journal:  Alzheimers Dement       Date:  2014-06-28       Impact factor: 21.566

6.  Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease.

Authors:  Winnie Qian; Corinne E Fischer; Tom A Schweizer; David G Munoz
Journal:  Curr Alzheimer Res       Date:  2018       Impact factor: 3.498

Review 7.  Apolipoprotein E in Alzheimer's disease and other neurological disorders.

Authors:  Philip B Verghese; Joseph M Castellano; David M Holtzman
Journal:  Lancet Neurol       Date:  2011-03       Impact factor: 44.182

8.  Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele.

Authors:  K Blennow; N Bogdanovic; I Alafuzoff; R Ekman; P Davidsson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

9.  Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Authors:  C M Wischik; P C Edwards; R Y Lai; M Roth; C R Harrington
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

10.  A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32.

Authors:  M Varret; J P Rabès; B Saint-Jore; A Cenarro; J C Marinoni; F Civeira; M Devillers; M Krempf; M Coulon; R Thiart; M J Kotze; H Schmidt; J C Buzzi; G M Kostner; S Bertolini; M Pocovi; A Rosa; M Farnier; M Martinez; C Junien; C Boileau
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.